Drugs & Targets Cota, Novartis form collaboration to advance real-world evidence in breast cancer therapies March 31, 2017Vol.43 No.13
Drugs & Targets Novartis CAR-T cell therapy for pediatric r/r B-cell ALL gets FDA Priority Review March 31, 2017Vol.43 No.13
Drugs & Targets BMS, Foundation Medicine form collaboration to identify predictive biomarkers across tumor types, immunotherapy agents March 31, 2017Vol.43 No.13
Drugs & Targets AbbVie, M2Gen announce collaboration for the ORIEN Avatar Research Program March 31, 2017Vol.43 No.13
Drugs & Targets Bavencio receives accelerated approval for Merkel cell carcinoma March 30, 2017Vol.40 No.03
Drugs & Targets Bavencio receives accelerated approval for Merkel cell carcinoma March 24, 2017Vol.43 No.12
Drugs & TargetsFree Kisqali gets FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor March 17, 2017Vol.43 No.11
Drugs & TargetsFree Keytruda gets accelerated approval for classical Hodgkin lymphoma March 17, 2017Vol.43 No.11
Drugs & TargetsFree FDA extends Keytruda PDUFA date for microsatellite instability-high cancer March 17, 2017Vol.43 No.11
Drugs & TargetsFree Mylan announces settlement, license deals with Genentech and Roche on Herceptin March 17, 2017Vol.43 No.11
